Christopher Sesi, MD
Ophthalmology · Novi, MINPI 1124655501
Payments from drug & device makers
Across 41 payments — averaging $55.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Apellis Pharmaceuticals, Inc.$182
- Biotissue Holdings Inc.$156
- Seagen Inc.$143
- Tarsus Pharmaceuticals, Inc.$142
- AbbVie$123
- plus $436 from 10 others
What the payments were for
- Food & beverage$2,01589%
- Education$24311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 15 | $1,077 |
| Apellis Pharmaceuticals, Inc. | 6 | $182 |
| Biotissue Holdings Inc. | 2 | $156 |
| Seagen Inc. | 2 | $143 |
| Tarsus Pharmaceuticals, Inc. | 1 | $142 |
| AbbVie | 2 | $123 |
| Sight Sciences, Inc. | 1 | $109 |
| Regeneron Healthcare Solutions, Inc. | 2 | $65 |
| NEW World Medical,inc. | 1 | $56 |
| Bausch & Lomb Americas Inc. | 3 | $56 |
| Glaukos Corporation | 1 | $35 |
| Lundbeck LLC | 1 | $28 |
| Dompe US, Inc. | 1 | $25 |
| Amgen | 1 | $22 |
| Rayner Intraocular Lenses Limited | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$492
- Clareon$241
- XDEMVY$142
- Hydrus Microstent$135
- OMNI(R) SURGICAL SYSTEM (US)$109
How this compares
$2,258 in reported general payments places this provider in the 65th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 13 | $4,106 |
| Prednisolone Acetate | 54 | $2,743 |
| Latanoprost | 201 | $2,658 |
| Brimonidine Tartrate | 96 | $2,425 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $1,282 |
| Ketorolac Tromethamine | 48 | $938 |
| MoxifloxacinMoxifloxacin Hcl | 39 | $793 |
| Timolol Maleate | 15 | $252 |
| Dorzolamide Hcl | 16 | $231 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Novi
- Mahdi BashaFraser$2.2M
- Thomas WubbenAnn Arbor$1.2M
- Manjool ShahAnn Arbor$745K
- Scott WesthouseGrand Rapids$525K
- Gregory KatzYpsilanti$495K
- Cagri BesirliAnn Arbor$441K
- David BrownSaint Joseph$432K
- Vinay AakaluAnn Arbor$429K
- Timothy PageBirmingham$324K
- David CookeSaint Joseph$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.